NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

GOVX

Geovax Labs Inc

May 13 • 04:00PM ET

0.9400

Dollar change +0.0149
Percentage change 1.61	%

Healthcare • Biotechnology • USA • NASD

Peers: INO NVAX VXRT ALT BNTX CVAC MOD HEPA ITRM HOOK

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-4.13	Insider Own	0.82%	Shs Outstand	15.19M	Perf Week	1.01%
Market Cap	14.29M	Forward P/E	-	EPS next Y	-0.95	Insider Trans	35.75%	Shs Float	15.07M	Perf Month	-7.84%
Income	-24.50M	PEG	-	EPS next Q	-0.46	Inst Own	5.60%	Short Float	5.94%	Perf Quarter	-40.13%
Sales	5.59M	P/S	2.56	EPS this Y	67.63%	Inst Trans	-67.23%	Short Ratio	1.68	Perf Half Y	-51.04%
Book/sh	0.57	P/B	1.65	EPS next Y	38.89%	ROA	-345.27%	Short Interest	0.90M	Perf Year	-40.88%
Cash/sh	0.49	P/C	1.92	EPS next 5Y	-	ROE	-616.17%	52W Range	0.73 - 11.18	Perf YTD	-61.94%
Dividend Est.	-	P/FCF	-	EPS past 5Y	78.99%	ROI	-310.20%	52W High	-91.59%	Beta	3.46
Dividend TTM	-	Quick Ratio	3.62	Sales past 5Y	-24.75%	Gross Margin	98.34%	52W Low	28.77%	ATR (14)	0.10
Dividend Ex-Date	-	Current Ratio	3.62	EPS Y/Y TTM	71.39%	Oper. Margin	-441.15%	RSI (14)	43.66	Volatility	7.47% 11.29%
Employees	17	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-438.17%	Recom	1.00	Target Price	10.70
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	81.87%	Payout	-	Rel Volume	0.43	Prev Close	0.93
Sales Surprise	-70.26%	EPS Surprise	-9.12%	Sales Q/Q	-	Earnings	Mar 27 AMC	Avg Volume	531.72K	Price	0.94
SMA20	0.82%	SMA50	-19.86%	SMA200	-57.91%	Trades		Volume	229,580	Change	1.61%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-15-25	Reiterated	D. Boral Capital	Buy	$18 → $14
Apr-15-25	Reiterated	Alliance Global Partners	Buy	$15 → $8.50
Nov-11-24	Initiated	Alliance Global Partners	Buy	$15
Jul-16-24	Initiated	ROTH MKM	Buy	$20
Nov-19-20	Initiated	Maxim Group	Buy	$8

May-08-25 09:00AM	GeoVax Highlights Dual Protective Potential of GEO-CM04S1 Following Presentation at the AAI Annual Meeting 2025 (NewMediaWire)
May-07-25 09:00AM	GeoVax Expands Gedeptin(R) Patent Portfolio (NewMediaWire)
May-06-25 03:00PM	GeoVax Applauds White House Executive Order Supporting U.S. Pharmaceutical Manufacturing; Highlights Progress in Domestic MVA Vaccine Production (NewMediaWire) -7.86%
May-01-25 08:58PM	GeoVax Labs, Inc. (GOVX) Q1 2025 Earnings Call Transcript (Seeking Alpha)
04:00PM	GeoVax Reports First Quarter 2025 Financial Results and Provides Business Update (NewMediaWire)
12:00PM	Loading…
Apr-29-25 12:00PM	GeoVax Presents Gedeptin(R) Clinical Data at the American Association for Cancer Research Annual Meeting (NewMediaWire)
Apr-24-25 04:02PM	GeoVax Responds to Detection of Clade I Mpox in North Carolina Wastewater (NewMediaWire) +17.92%
12:00PM	GeoVax Highlights Strong Clinical Results Following Presentation of Multi-Antigen COVID-19 Vaccine at the 25th Annual World Vaccine Congress (NewMediaWire)
Apr-23-25 09:00AM	GeoVax to Report First Quarter 2025 Financial Results and Provide Corporate Update on May 1, 2025 (NewMediaWire)
Apr-22-25 09:00AM	GeoVax Appoints Dr. Senthil Ranganathan as Vice President, Technical Development and CMC Operations (NewMediaWire) +7.60%
Apr-16-25 04:00PM	GeoVax Highlights New Study Demonstrating the Strength of Multi-Antigen COVID-19 Vaccine Candidates (NewMediaWire) +6.09% -8.08%
10:15AM	GeoVax Labs price target lowered to $14 from $18 at D. Boral Capital (TipRanks)
09:00AM	GeoVax Provides Update on BARDA Project NextGen and Outlines 2025 Business Momentum (NewMediaWire)
07:00AM	Presenting on Emerging Growth Conference 81 Day 2 on April 17; Register to live stream (GlobeNewswire)
Apr-15-25 01:25PM	GeoVax to Present at the Emerging Growth Conference on April 16, 2025 (NewMediaWire) -20.50%
09:00AM	Loading…
09:00AM	GeoVax to Present Clinical Data at Upcoming April Industry Events (NewMediaWire)
07:00AM	Presenting on Emerging Growth Conference 81 Day 1 on April 16; Register to live stream (GlobeNewswire)
Apr-09-25 09:00AM	GeoVax Receives USPTO Notice of Allowance for Marburg Hemorrhagic Fever Vaccine Patent (NewMediaWire) +7.21%
Mar-27-25 08:53PM	GeoVax Labs, Inc. (GOVX) Q4 2024 Earnings Call Transcript (Seeking Alpha) -7.30% -12.60%
04:00PM	GeoVax Reports 2024 Year-End Financial Results and Provides Business Update (NewMediaWire)
Mar-26-25 07:00AM	Presenting on the Emerging Growth Conference 80 Day 2 on March 27 Register Now (GlobeNewswire)
Mar-25-25 07:00AM	Presenting on the Emerging Growth Conference 80, Day 1 on March 26 - Register Now (GlobeNewswire)
Mar-24-25 08:00AM	GeoVax Labs Announces $4.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (NewMediaWire) +6.87%
Mar-17-25 09:00AM	GeoVax to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 27, 2025 (NewMediaWire)
Mar-12-25 09:00AM	GeoVax Establishing Strategic Presence in Europe With Initial Footprint in the UK (NewMediaWire)
Mar-11-25 09:00AM	GeoVax to Present at the 37th Annual Roth Conference (NewMediaWire)
Mar-04-25 09:00AM	Registration is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event MPOX 2025: Navigating the Global Public Health Emergency Featuring GeoVax CEO On March 6, 2025 (NewMediaWire) +14.57%
Mar-03-25 09:00AM	GeoVax Highlights the Critical Role of MVA-Based Vaccines in U.S. Biodefense Strategy (NewMediaWire)
Feb-27-25 02:22PM	GeoVax Response to WHO's Third Declaration of Mpox as a Public Health Emergency of International Concern (NewMediaWire)
Feb-24-25 09:00AM	GeoVax Highlights the Role of MVA-Based Vaccines in Advancing Public Health Preparedness (NewMediaWire) -8.38%
09:00AM	Loading…
Feb-19-25 09:00AM	Mpox Clade 1 in the U.S. Highlights the Need for Vaccine Supply Diversification (NewMediaWire)
06:00AM	Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now (GlobeNewswire)
Feb-18-25 09:25AM	GeoVax Pledges Continued Support for Vaccine Innovation, Transparency, and Public Health (NewMediaWire)
Feb-17-25 09:00AM	GeoVax to Present at the Emerging Growth Conference on February 19, 2025 (NewMediaWire)
Feb-11-25 09:00AM	GeoVax Congratulates Dr. Valerie Montgomery Rice on Receiving the 2025 Healthcare Champions Lifetime Achievement Award (NewMediaWire)
Feb-05-25 09:00AM	GeoVax Anticipates Significant 2025 Progress With Catalyst-Rich Milestones Across Key Programs (NewMediaWire)
Feb-04-25 09:00AM	GeoVax to Showcase Advancements in Vaccines & Immunotherapies at the 2025 BIO CEO & Investor Conference (NewMediaWire)
Feb-03-25 09:00AM	GeoVax Announces Strategic Integration of AI in Support of President Trump's Stargate Initiative (NewMediaWire) -7.33%
Jan-29-25 09:00AM	Strengthening America's Biosecurity: GeoVax Advances Domestic Vaccine Capability (NewMediaWire)
Jan-27-25 09:00AM	GeoVax Advanced MVA Manufacturing Process: Aimed to Enhance Vaccine Supply Worldwide (NewMediaWire) -6.28%
Jan-15-25 09:00AM	GeoVax Announces Major Gedeptin Milestone With Plans of Phase 2 Trial (NewMediaWire) +6.64%
07:00AM	Presenting on the Emerging Growth Conference 78 Day 2 on January 16 Register Now (GlobeNewswire)
Jan-14-25 07:00AM	Presenting on the Emerging Growth Conference 78 Day 1 on January 15 Register Now (GlobeNewswire)
Jan-13-25 09:00AM	GeoVax Achieves Significant Progress in Next-Generation COVID-19 Vaccine Development Throughout 2024 (NewMediaWire)
Jan-08-25 09:00AM	GeoVax to Review 2024 Progress at the Emerging Growth Conference on January 16, 2025 (NewMediaWire) -9.09%
Jan-06-25 09:00AM	GeoVax to Review 2024 Progress at Biotech Showcase During J.P. Morgan Healthcare Week 2025 (NewMediaWire)
Dec-09-24 09:00AM	GeoVax Receives Notice of Allowance For Cancer Vaccine Patent (GlobeNewswire)
Nov-26-24 09:00AM	GeoVax to Present at the Noble Capital Markets Twentieth Annual Emerging Growth Equity Conference (GlobeNewswire) -10.30%
Nov-19-24 09:00AM	GeoVax Announces Positive Interim Data Review for Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia (GlobeNewswire)
Nov-12-24 04:00PM	GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -16.92%
07:07AM	GeoVax Labs initiated with a Buy at Alliance Global Partners (TipRanks)
Nov-05-24 09:00AM	GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024 (GlobeNewswire)
Oct-02-24 09:00AM	GeoVax to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference (GlobeNewswire)
Sep-25-24 07:00AM	Presenting on the Emerging Growth Conference 75 Day 2 on September 26 (GlobeNewswire)
Sep-24-24 07:00AM	Presenting on the Emerging Growth Conference 75 Day 1 on September 25 Register Now (GlobeNewswire)
Sep-03-24 11:54PM	GeoVax Labs, Inc. (GOVX): A Hot Penny Stock On The Move (Insider Monkey) -15.04%
09:00AM	GeoVax to Participate in Upcoming Investor Conferences in September (GlobeNewswire)
Sep-02-24 12:17PM	10 Hot Penny Stocks On the Move (Insider Monkey)
Aug-28-24 08:59PM	GeoVax to Raise Approximately $5.0 Million of Gross Proceeds in Offering Priced At-the-Market (GlobeNewswire) -16.25%
Aug-21-24 09:00AM	Registration is Now Open for Tribe Public's Webinar Event 'Now Is Not the Time to Monkey(pox) Around' Featuring GeoVax Lab's CEO (GlobeNewswire) +47.01%
07:00AM	Presenting on the Emerging Growth Conference 74 Day 2 on August 22 Register Now (GlobeNewswire)
Aug-20-24 07:45AM	GeoVax to Raise Approximately $8.5 Million of Gross Proceeds in Offering Priced Above-the-Market (GlobeNewswire) -20.56%
07:00AM	Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now (GlobeNewswire)
Aug-19-24 05:16PM	WHO declares mpox a public health emergency as variant emerges (Yahoo Finance Video)
Aug-15-24 09:00AM	GeoVax to Present at the Emerging Growth Conference on August 21, 2024 (GlobeNewswire)
Aug-08-24 09:00AM	GeoVax Appoints Teresa Lambe, Acclaimed Professor of Vaccinology and Immunology at the Oxford Vaccine Group, to Its Scientific Advisory Board (GlobeNewswire) +5.06%
Aug-06-24 04:00PM	GeoVax Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Jul-31-24 10:15AM	Update: GeoVax Announces Phase 2 Plans for Gedeptin Cancer Therapy Following Clinical Advisory Committee Review (GlobeNewswire)
09:00AM	GeoVax Announces Phase 2 Plans for Gedeptin Cancer Therapy Following Clinical Advisory Committee Review (GlobeNewswire)
Jul-30-24 09:00AM	GeoVax to Report Second Quarter 2024 Financial Results and Provide Corporate Update on August 6, 2024 (GlobeNewswire) -8.26%
Jul-17-24 07:00AM	Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now (GlobeNewswire)
Jul-16-24 12:54PM	GeoVax (GOVX) Stock Pops Ahead of July 18 Catalyst (InvestorPlace) +5.34%
09:00AM	GeoVax to Present at the Emerging Growth Conference on July 18, 2024 (NewMediaWire)
07:00AM	Presenting on the Emerging Growth Conference 73 Day 1 on July 17 Register Now (GlobeNewswire)
Jul-11-24 08:30AM	GeoVax to Raise Approximately $3.1 Million of Gross Proceeds in Offering Priced At-the-Market (NewMediaWire) -9.38%
Jul-09-24 09:00AM	GeoVax Provides First Half 2024 Business Update (NewMediaWire) -12.20%
Jun-27-24 02:23PM	Why Is GeoVax (GOVX) Stock Up 110% Today? (InvestorPlace) +76.18%
09:00AM	GeoVax Partners with Allucent to Conduct Phase 2b Clinical Study of Next-Generation COVID-19 Vaccine Candidate with Funding from BARDA (NewMediaWire)
07:34AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace)
Jun-26-24 07:41AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace) -8.41%
Jun-20-24 10:00AM	Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth (GlobeNewswire)
Jun-18-24 07:00AM	GeoVax Receives BARDA Project NextGen Award to Conduct Phase 2b Clinical Study Evaluating the Company's Next-Generation COVID-19 Vaccine Candidate, GEO-CM04S1 (NewMediaWire) +71.17%
Jun-07-24 07:22AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace) -6.40%
May-29-24 09:00AM	GeoVax to Present at BIO International Convention 2024 (NewMediaWire) +7.98%
May-17-24 08:00AM	GeoVax to Raise Approximately $1.3 Million of Gross Proceeds in Offering Priced At-the-Market (NewMediaWire)
May-15-24 08:19AM	GeoVax Labs, Inc. (NASDAQ:GOVX) Q1 2024 Earnings Call Transcript (Insider Monkey)
07:53AM	GOVX Stock Earnings: Geovax Labs Beats EPS for Q1 2024 (InvestorPlace)
May-14-24 04:00PM	GeoVax Reports First Quarter 2024 Financial Results and Provides Business Update (NewMediaWire)
May-07-24 09:00AM	GeoVax to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024 (NewMediaWire)
Apr-04-24 12:30PM	GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine (GlobeNewswire)
Mar-28-24 09:00AM	GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress (GlobeNewswire) +8.11%
Mar-12-24 09:00AM	GeoVax to Present at the 36th Annual Roth Conference (GlobeNewswire)
Mar-06-24 09:00AM	GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System (GlobeNewswire)
Mar-02-24 08:45AM	GeoVax Labs, Inc. (NASDAQ:GOVX) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-29-24 04:00PM	GeoVax Reports 2023 Year-End Financial Results and Provides Business Update (GlobeNewswire)
Feb-22-24 09:00AM	GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024 (GlobeNewswire)
Feb-19-24 09:00AM	GeoVax to Present at the 2024 BIO CEO & Investor Conference (GlobeNewswire)
Feb-13-24 09:00AM	GeoVax Announces Multiple Patent Issuances and Allowances (GlobeNewswire)
Feb-06-24 09:00AM	GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster (GlobeNewswire)
Jan-29-24 09:00AM	GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement (GlobeNewswire) -8.25%

GeoVax Labs, Inc. is a clinical-stage biotechnology company, which engages in the development of human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. It focuses on preventive vaccines against hemorrhagic fever viruses such as Ebola, Sudan, Marburg, and Lassa fever, the Zika virus and malaria, and human immunodeficiency virus, as well as immunotherapies for solid tumor cancers. The company was founded in June 1988 and is headquartered in Smyrna, GA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SPENCER JOHN N JR	Director	Apr 10 '25	Buy	0.98	10,000	9,800	11,402	Apr 11 01:23 PM
Sharkey John W.	VP, Business Development	Apr 10 '25	Buy	0.99	6,000	5,940	6,191	Apr 10 04:01 PM
DODD DAVID A	President, CEO	Apr 01 '25	Buy	1.08	10,000	10,800	36,661	Apr 01 04:46 PM
Reynolds Mark	CFO	Mar 31 '25	Buy	1.08	6,800	7,343	14,013	Mar 31 04:04 PM
DODD DAVID A	President, CEO	Aug 09 '24	Buy	1.95	8,000	15,600	26,661	Aug 12 08:47 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GOVX

Geovax Labs Inc

Upgrade your FINVIZ experience